BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Trial status

Accepting patients

Phase
Phase 1
Enrollment
130
Last Updated
5 days ago
Patient Screener

Participating Centers

There are 12 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BMS-986453
  • Cyclophosphamide
  • Fludarabine

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Part A

Not yet accepting

Part B, Cohort 1

Not yet accepting

Part B, Cohort 2

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.